CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 61 enrolled
Drug / intervention
aripiprazole +1 moredrug
Likely dose
aripiprazole 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00706589
NCT00706589Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder

Korea Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Jun 27, 2008·Updated Jul 26, 2013

In Brief

A Phase 3 clinical trial evaluating aripiprazole and placebo for Chronic Motor or Vocal Tic Disorder and Tourette's Disorder. Completed, enrolled 61 participants across 6 sites.

Detailed Summary

The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6\~18 years with chronic tic disorders or Tourette's disorder

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Motor or Vocal Tic Disorder, Tourette's Disorder
CountriesSouth Korea
CollaboratorsOtsuka Pharmaceutical Co., Ltd.

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2008
Enrollment StartOct 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.0 years ago

Interventions

aripiprazoledrug

Initial dose : 2mg, Maximum dose : 20mg

placebodrug

Initial dose: 2mg, Maximum dose:20mg